TFF Pharmaceuticals, Inc. Common Stock
TFFP
TFFP was delisted on the 12th of December, 2024.
59 hedge funds and large institutions have $54.5M invested in TFF Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 15 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 19
6% less funds holding
Funds holding: 63 → 59 (-4)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
43% less capital invested
Capital invested by funds: $96.1M → $54.5M (-$41.6M)
63% less call options, than puts
Call options by funds: $649K | Put options by funds: $1.75M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$5.34M |
| 2 |
Renaissance Technologies
New York
|
+$1.29M |
| 3 |
PCM
Princeton Capital Management
Red Bank,
New Jersey
|
+$1.21M |
| 4 |
Two Sigma Investments
New York
|
+$1.03M |
| 5 |
GS
Gagnon Securities
New York
|
+$884K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$21.2M |
| 2 |
ACM
Altium Capital Management
New York
|
-$3.66M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.8M |
| 4 |
Millennium Management
New York
|
-$1.39M |
| 5 |
PM
Precept Management
Dallas,
Texas
|
-$1.01M |
TFFP Hedge Fund Activity: Q2 2021 in Review
59 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in TFF Pharmaceuticals, Inc. Common Stock (TFFP) for Q2 2021, worth a combined $54.5M — down 43% from $96.1M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TFFP and 11 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 21 added.
The largest buyer was DRW Securities, adding an estimated $5.34M. The largest seller was Corriente Advisors, exiting entirely with an estimated $21.2M sold.
- 59 institutional investors held TFF Pharmaceuticals, Inc. Common Stock (TFFP) as of Q2 2021, down from 63 in Q1 2021.
- Funds reported $54.5M of TFF Pharmaceuticals, Inc. Common Stock stock for Q2 2021, down 43% quarter-over-quarter.
- 11 funds opened new TFF Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 15 closed out, a net change of -4 holders.
- The largest TFF Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was DRW Securities, an estimated $5.34M added.
- The largest TFF Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was Corriente Advisors, an estimated $21.2M sold.
Based on aggregated 13F filings for Q2 2021.